Scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes.
BioInvent International AB and co-development partner ThromboGenics NV have announced positive results of a TB-402 Phase 2 trial, evaluating the product’s efficacy and safety for the prevention of venous thromboembolism after orthopaedic surgery.
Renovo Group plc, which develops drugs to reduce scarring, improve wound healing, and enhance tissue regeneration, announces that its first EU Phase 3 trial for Juvista in scar revision surgery (REVISE) did not meet its primary or secondary endpoints.
Irish drug developer Shire Plc. said its fourth-quarter profit fell on higher costs, but the results met Wall Street expectations. The company earned $165.1 million, down from $174.3 million.
Eli Lilly and Co. named company insider Sue Mahony as president of its cancer drug business. The change is effective immediately. Mahony has worked at Eli Lilly for about 10 years, the company said.
In order to ensure smooth operation during bioanalytical studies, a novel model, where a principal investigator with direct control over the entire study is the core of the project, has been developed.
The Automation Partnership, a leader in the design and development of innovative automation for life science applications, has announced its micro bioreactor system, ambr, is now available with integrated Beckman Coulter Vi-CELL Cell Viability Analyser.
PerkinElmer Inc. announced the launch of the Frontier Infrared Spectrometer, a high performance infrared (FT-IR) spectrometer built using PerkinElmer’s industry-leading spectroscopy expertise.
Fluidigm Corporation announced the pricing of its initial public offering of 5,558,333 shares of its common stock at a price to the public of $13.50 per share. The shares of common stock have been approved to trade on The NASDAQ Global Market under the symbol "FLDM."
Auxilium Pharmaceuticals Inc. said its fourth-quarter loss widened, even though revenue grew 29 percent, as the biopharmaceutical company incurred growing expenses tied to its Dupuytren's contracture treatment Xiaflex.
For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots.
A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade.
Irish drug maker Covidien PLC said it received Food and Drug Administration approval for a generic version of Johnson & Johnson's Duragesic pain patch. The patch manages persistent, moderate to severe chronic pain in opiod-tolerant patients.
Idenix Pharmaceuticals Inc. revealed that federal regulators have temporarily halted studies of an HIV and AIDS drug that the company developed. Idenix said it was informed by its partner ViiV Healthcare that the FDA placed a clinical hold on studies of the drug.